Drugs / AN9025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07252479 | Jan 2026 → Jan 2028 expected | — | Adlai Nortye Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN9025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07252479 ↗ |
| Action | Inhibit | “pan-RAS (ON) inhibitor” NCT07252479 ↗ |
| Modality | Small molecule | “AN9025 is a novel, oral, small molecule pan-RAS (ON) inhibitor” NCT07252479 ↗ |
| Route | Oral | “Oral administration of AN9025 capsules” NCT07252479 ↗ |